ProPhase Labs PRPH Stock
ProPhase Labs Price Chart
ProPhase Labs PRPH Financial and Trading Overview
| ProPhase Labs stock price | 6.52 USD |
| Previous Close | 7.36 USD |
| Open | 7.39 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1200 |
| Day's Range | 7.39 - 7.67 USD |
| 52 Week Range | 6.6 - 15.25 USD |
| Volume | 58.34K USD |
| Avg. Volume | 77.82K USD |
| Market Cap | 128.36M USD |
| Beta (5Y Monthly) | -0.349647 |
| PE Ratio (TTM) | 19.657894 |
| EPS (TTM) | -0.98 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 24, 2022 |
| 1y Target Est | 16.67 USD |
PRPH Valuation Measures
| Enterprise Value | 122.57M USD |
| Trailing P/E | 19.657894 |
| Forward P/E | 67.90909 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.3594246 |
| Price/Book (mrq) | 2.1000843 |
| Enterprise Value/Revenue | 1.298 |
| Enterprise Value/EBITDA | 9.367 |
Trading Information
ProPhase Labs Stock Price History
| Beta (5Y Monthly) | -0.349647 |
| 52-Week Change | -28.10% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.25 USD |
| 52 Week Low | 6.6 USD |
| 50-Day Moving Average | 8.31 USD |
| 200-Day Moving Average | 9.32 USD |
PRPH Share Statistics
| Avg. Volume (3 month) | 77.82K USD |
| Avg. Daily Volume (10-Days) | 103.57K USD |
| Shares Outstanding | 17.18M |
| Float | 12.86M |
| Short Ratio | 3.15 |
| % Held by Insiders | 22.83% |
| % Held by Institutions | 16.40% |
| Shares Short | 346.74K |
| Short % of Float | 2.61% |
| Short % of Shares Outstanding | 2.02% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 6.90% |
| Operating Margin (ttm) | 8.81% |
| Gross Margin | 55.60% |
| EBITDA Margin | 13.85% |
Management Effectiveness
| Return on Assets (ttm) | 5.33% |
| Return on Equity (ttm) | 10.31% |
Income Statement
| Revenue (ttm) | 94.42M USD |
| Revenue Per Share (ttm) | 5.84 USD |
| Quarterly Revenue Growth (yoy) | -59.39% |
| Gross Profit (ttm) | 70.65M USD |
| EBITDA | 13.09M USD |
| Net Income Avi to Common (ttm) | 6.52M USD |
| Diluted EPS (ttm) | 0.38 |
| Quarterly Earnings Growth (yoy) | -95.59% |
Balance Sheet
| Total Cash (mrq) | 15.56M USD |
| Total Cash Per Share (mrq) | 0.92 USD |
| Total Debt (mrq) | 14.1M USD |
| Total Debt/Equity (mrq) | 23.53 USD |
| Current Ratio (mrq) | 3.318 |
| Book Value Per Share (mrq) | 3.557 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 8.74M USD |
| Levered Free Cash Flow (ttm) | 7.51M USD |
Profile of ProPhase Labs
| Country | United States |
| State | NY |
| City | Garden City |
| Address | 711 Stewart Avenue |
| ZIP | 11530 |
| Phone | 215 345 0919 |
| Website | https://www.prophaselabs.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 129 |
ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Q&A For ProPhase Labs Stock
What is a current PRPH stock price?
ProPhase Labs PRPH stock price today per share is 6.52 USD.
How to purchase ProPhase Labs stock?
You can buy PRPH shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ProPhase Labs?
The stock symbol or ticker of ProPhase Labs is PRPH.
Which industry does the ProPhase Labs company belong to?
The ProPhase Labs industry is Diagnostics & Research.
How many shares does ProPhase Labs have in circulation?
The max supply of ProPhase Labs shares is 18.05M.
What is ProPhase Labs Price to Earnings Ratio (PE Ratio)?
ProPhase Labs PE Ratio is now.
What was ProPhase Labs earnings per share over the trailing 12 months (TTM)?
ProPhase Labs EPS is -0.98 USD over the trailing 12 months.
Which sector does the ProPhase Labs company belong to?
The ProPhase Labs sector is Healthcare.
ProPhase Labs PRPH included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
- {{ link.label }} {{link}}